Home » Stocks » CVLB

Conversion Labs, Inc (CVLB)

Stock Price: $17.72 USD 4.85 (37.68%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $18.65 +0.93 (5.25%) Jan 26, 7:55 PM
Market Cap 347.79M
Revenue (ttm) 28.34M
Net Income (ttm) -30.61M
Shares Out 14.67M
EPS (ttm) -2.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $17.72
Previous Close $12.87
Change ($) 4.85
Change (%) 37.68%
Day's Open 12.68
Day's Range 12.51 - 18.44
Day's Volume 2,759,199
52-Week Range 5.99 - 18.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth qua...

GlobeNewsWire - 2 weeks ago

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and ps...

GlobeNewsWire - 2 weeks ago

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has been invited to present at H.C. Wainwright's BioConnect Confere...

GlobeNewsWire - 3 weeks ago

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, reported its annualized revenue run-rate reached a r...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, has officially launched its new Veritas MD telehealt...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has received approval to uplist to the Nasdaq Capital ...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed expert Life Sciences attorney, Eric H. ...

Seeking Alpha - 2 months ago

Conversion Labs' (CVLB) CEO Justin Schreiber on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has appointed Roberto Simon to its board...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, will hold a conference call on Monday, N...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has closed on approximately $14.5 mill...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB) (OTCQB: CVLBD), a direct-to-consumer telemedicine and wellness company, has signed a licensing agreement with Re...

Seeking Alpha - 3 months ago

Dizzying triple-digit rate growth looks to be continuing for quite a while due to the introduction of a new platform. The company can add brands and products almost at will. The platform and m...

About CVLB

Conversion Labs operates as a direct response healthcare company that provides over the counter products and prescription medications to consumers worldwide. The company's products include Shapiro MD, a shampoo, conditioner, and leave-in-foamer for treating hair loss; iNR Wellness MD, a nutritional supplement for immune and gut support; RexMD for the treatment of cold sores, mental health, and various other medical conditions faced by men; SOSRx, a telemedicine brand that offers prescription medications and over-the-counter emergency preparatio... [Read more...]

Industry
Pharmaceutical Retailers
Founded
1994
CEO
Justin Schreiber
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
CVLB
Full Company Profile

Financial Performance

In 2019, CVLB's revenue was $12.47 million, an increase of 49.79% compared to the previous year's $8.32 million. Losses were -$3.14 million, 152.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CVLB stock is "Strong Buy" and the 12-month stock price forecast is 15.00.

Price Target
$15.00
Analyst Consensus: Strong Buy